7th Eurasian Hematology Oncology Summit

 

7th Eurasian Hematology Oncology Summit
C

How I Treat HL in 2020: What Is the Role of PET-Adapted Strategies? Is BV Superior to Immune CPIs in R/R Disease?

By 7th Eurasian Hematology Oncology Summit FEATURING Christian Gisselbrecht
By 7th Eurasian Hematology Oncology Summit FEATURING Christian Gisselbrecht
200 views
September 30, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

15:43
Incyte

Importance of Early Management of Patients with Myelofibrosis (MF)

Feat. P. Bose, R. Rampal

Featured Video

18:30
Pfizer Hematology

Expert Case Review: A Treatment Option for Adult Patients With Stage…

Feat. A. Whiteley
Lymphoma
14:50

How I Treat Follicular Lymphoma in 2020: Rituximab vs. WW Strategy, …

7th Eurasian Hematology Oncology Summit

G. Gaidano

60 views
19:51

How I Treat DLBCL in 2020: Can Radiotherapy Be Omitted in PET Era? I…

7th Eurasian Hematology Oncology Summit

U. Vitolo

46 views
23:29

2020 Update on IO in R/R cHL: Is Long-Term Therapy w/ Nivo Feasible …

7th Eurasian Hematology Oncology Summit

T. Tuglular

136 views
15:27

How I Treat HL in 2020: What Is the Role of PET-Adapted Strategies? …

7th Eurasian Hematology Oncology Summit

C. Gisselbrecht

200 views
21:20

How I Treat Mantle Cell Lymphoma in 2020: Induction Options, ASCT, a…

7th Eurasian Hematology Oncology Summit

C. Schiffer

694 views